We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 266

Trump’s 2-for-1 Executive Order, its Impact on FDA, and the Significance of “Significant”
  • Arent Fox LLP
  • USA
  • February 10 2017

On the heels of a January 20, 2017 memorandum freezing the release of any new or pending regulations until they have been reviewed and approved by


Robert J. Anello
  • Morvillo Abramowitz Grand Iason & Anello PC

Paul S. Gadiock
  • Arent Fox LLP

Emily M. Leongini
  • Arent Fox LLP

Zhengyu Tang
  • Sidley Austin LLP

Anthony V. Lupo
  • Arent Fox LLP

Robert R. Clark
  • Taft Stettinius & Hollister LLP

Andrew J. Shin
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC

Clark Kent Ervin
  • Squire Patton Boggs

R. Neal Martin
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC